Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium

Equillium Inc. , a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced a presentation at the 18th...

Related Keywords

California ,United States ,San Diego ,Adrianj Giovannone , ,Translational Science Early Development At Equillium ,Equillium Inc ,Biocon ,Nasdaq ,Ono Pharmaceutical Co Ltd ,Scripps Seaside Forum ,Annual Peptide Therapeutics Symposium ,Peptide Stapling ,Better Stability ,Loral Delivery ,Associate Director ,Translational Science ,Early Development ,Celiac Disease ,Multi Cytokine Inhibition ,Multi Cytokine Platform ,Biocon Limited ,Markets ,